KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Gross Margin (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Gross Margin for 16 consecutive years, with 82.56% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 332.0% to 82.56% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 83.62% through Dec 2025, down 68.0% year-over-year, with the annual reading at 83.62% for FY2025, 68.0% down from the prior year.
  • Gross Margin for Q4 2025 was 82.56% at Halozyme Therapeutics, down from 84.41% in the prior quarter.
  • The five-year high for Gross Margin was 86.42% in Q1 2022, with the low at 74.62% in Q3 2023.
  • Average Gross Margin over 5 years is 81.15%, with a median of 82.14% recorded in 2025.
  • The sharpest move saw Gross Margin plummeted -811bps in 2023, then skyrocketed 862bps in 2024.
  • Over 5 years, Gross Margin stood at 78.84% in 2021, then decreased by -3bps to 76.79% in 2022, then grew by 1bps to 77.27% in 2023, then rose by 11bps to 85.89% in 2024, then dropped by -4bps to 82.56% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 82.56%, 84.41%, and 85.77% for Q4 2025, Q3 2025, and Q2 2025 respectively.